Rebecca E Amariglio1, Elizabeth C Mormino2, Alison C Pietras2, Gad A Marshall2, Patrizia Vannini2, Keith A Johnson2, Reisa A Sperling2, Dorene M Rentz2. 1. From the Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital (R.E.A., A.C.P., G.A.M., P.V., K.A.J., R.A.S., D.M.R.), and the Departments of Neurology (R.E.A., E.C.M., G.A.M., P.V., K.A.J., R.A.S., D.M.R.) and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston, MA. ramariglio@partners.org. 2. From the Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital (R.E.A., A.C.P., G.A.M., P.V., K.A.J., R.A.S., D.M.R.), and the Departments of Neurology (R.E.A., E.C.M., G.A.M., P.V., K.A.J., R.A.S., D.M.R.) and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Abstract
OBJECTIVE: To determine whether neuroimaging biomarkers of amyloid-β (Aβ) and neurodegeneration (ND) are associated with greater self-reported subjective cognitive concerns (SCC) in clinically normal older individuals. METHODS: A total of 257 participants underwent Pittsburgh compound B PET, PET with fluorodeoxyglucose (18)F, and structural MRI, as well as a battery of neuropsychological measures including several questionnaires regarding SCC. Individuals were classified into 4 biomarker groups: biomarker negative (Aβ-/ND-), amyloidosis alone (Aβ+/ND-), amyloidosis plus ND (Aβ+/ND+), and ND alone (Aβ-/ND+). RESULTS: Both Aβ and ND were independently associated with greater SCC controlling for objective memory performance. By contrast, neither Aβ nor ND was associated with objective memory performance controlling for SCC. Further examination revealed greater SCC in individuals with Aβ or ND positivity compared to biomarker-negative individuals. In addition, greater SCC predicted Aβ positivity when controlling for ND status. CONCLUSIONS: When individuals were grouped by biomarker status, those who were positive on Aβ or ND had the highest report of SCC compared to biomarker-negative individuals. Findings were consistent when SCC was used to predict Aβ positivity. Taken together, results suggest that both Aβ and ND are associated with SCC, independent of objective memory performance. Enrichment of individuals with SCC may increase likelihood of Aβ and ND markers in potential participants for secondary prevention trials.
OBJECTIVE: To determine whether neuroimaging biomarkers of amyloid-β (Aβ) and neurodegeneration (ND) are associated with greater self-reported subjective cognitive concerns (SCC) in clinically normal older individuals. METHODS: A total of 257 participants underwent Pittsburgh compound B PET, PET with fluorodeoxyglucose (18)F, and structural MRI, as well as a battery of neuropsychological measures including several questionnaires regarding SCC. Individuals were classified into 4 biomarker groups: biomarker negative (Aβ-/ND-), amyloidosis alone (Aβ+/ND-), amyloidosis plus ND (Aβ+/ND+), and ND alone (Aβ-/ND+). RESULTS: Both Aβ and ND were independently associated with greater SCC controlling for objective memory performance. By contrast, neither Aβ nor ND was associated with objective memory performance controlling for SCC. Further examination revealed greater SCC in individuals with Aβ or ND positivity compared to biomarker-negative individuals. In addition, greater SCC predicted Aβ positivity when controlling for ND status. CONCLUSIONS: When individuals were grouped by biomarker status, those who were positive on Aβ or ND had the highest report of SCC compared to biomarker-negative individuals. Findings were consistent when SCC was used to predict Aβ positivity. Taken together, results suggest that both Aβ and ND are associated with SCC, independent of objective memory performance. Enrichment of individuals with SCC may increase likelihood of Aβ and ND markers in potential participants for secondary prevention trials.
Authors: Keith A Johnson; Matt Gregas; John A Becker; Catherine Kinnecom; David H Salat; Erin K Moran; Erin E Smith; Jonathan Rosand; Dorene M Rentz; William E Klunk; Chester A Mathis; Julie C Price; Steven T Dekosky; Alan J Fischman; Steven M Greenberg Journal: Ann Neurol Date: 2007-09 Impact factor: 10.422
Authors: Sarah Tomaszewski Farias; Dan Mungas; Bruce R Reed; Deborah Cahn-Weiner; William Jagust; Kathleen Baynes; Charles Decarli Journal: Neuropsychology Date: 2008-07 Impact factor: 3.295
Authors: Dorene M Rentz; Rebecca E Amariglio; J Alex Becker; Meghan Frey; Lauren E Olson; Katherine Frishe; Jeremy Carmasin; Jacqueline E Maye; Keith A Johnson; Reisa A Sperling Journal: Neuropsychologia Date: 2011-06-12 Impact factor: 3.139
Authors: A J Saykin; H A Wishart; L A Rabin; R B Santulli; L A Flashman; J D West; T L McHugh; A C Mamourian Journal: Neurology Date: 2006-09-12 Impact factor: 9.910
Authors: Lotte Gerritsen; Hannie C Comijs; Yolanda van der Graaf; Arnoud J G Knoops; Brenda W J H Penninx; Mirjam I Geerlings Journal: Biol Psychiatry Date: 2011-03-24 Impact factor: 13.382
Authors: Dorene M Rentz; Joseph J Locascio; John A Becker; Erin K Moran; Elisha Eng; Randy L Buckner; Reisa A Sperling; Keith A Johnson Journal: Ann Neurol Date: 2010-03 Impact factor: 10.422
Authors: Dustin B Hammers; Taylor J Atkinson; Bonnie C A Dalley; Kayla R Suhrie; Kevin P Horn; Kelli M Rasmussen; Britney E Beardmore; Lance D Burrell; Kevin Duff; John M Hoffman Journal: Am J Alzheimers Dis Other Demen Date: 2017-04-12 Impact factor: 2.035
Authors: Dorene M Rentz; Blair K Weiss; Emily G Jacobs; Sara Cherkerzian; Anne Klibanski; Anne Remington; Harlyn Aizley; Jill M Goldstein Journal: Menopause Date: 2017-04 Impact factor: 2.953
Authors: Sepideh Shokouhi; Alexander C Conley; Suzanne L Baker; Kimberly Albert; Hakmook Kang; Harry E Gwirtsman; Paul A Newhouse Journal: Neurobiol Aging Date: 2019-05-23 Impact factor: 4.673
Authors: Yakeel T Quiroz; Reisa A Sperling; Daniel J Norton; Ana Baena; Joseph F Arboleda-Velasquez; Danielle Cosio; Aaron Schultz; Molly Lapoint; Edmarie Guzman-Velez; John B Miller; Leo A Kim; Kewei Chen; Pierre N Tariot; Francisco Lopera; Eric M Reiman; Keith A Johnson Journal: JAMA Neurol Date: 2018-05-01 Impact factor: 18.302